Page 111 - Read Online

Mauri et al. Mini-invasive Surg 2022;6:49 https://dx.doi.org/10.20517/2574-1225.2022.34 Page 13 of 13

37. Valgimigli M, Bueno H, Byrne RA, et al; ESC Scientific Document Group. , ESC Committee for Practice Guidelines (CPG)., ESC
National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration
with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and
of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39:213-60. DOI PubMed
38. Ruel M, Kulik A, Rubens FD, et al. Late incidence and determinants of reoperation in patients with prosthetic heart valves. Eur J
Cardiothorac Surg 2004;25:364-70. DOI PubMed
39. De Marchena E, Mesa J, Pomenti S, et al. Thrombus formation following transcatheter aortic valve replacement. JACC Cardiovasc
Interv 2015;8:728-39. DOI PubMed
40. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med
2015;373:2015-24. DOI PubMed
41. Del Trigo M, Muñoz-Garcia AJ, Wijeysundera HC, et al. Incidence, timing, and predictors of valve hemodynamic deterioration after
transcatheter aortic valve replacement: multicenter registry. J Am Coll Cardiol 2016;67:644-55. DOI PubMed
42. Overtchouk P, Guedeney P, Rouanet S, et al. Long-term mortality and early valve dysfunction according to anticoagulation use: the
FRANCE TAVI registry. J Am Coll Cardiol 2019;73:13-21. DOI PubMed
43. Montalescot G. Apixaban and valve thrombosis after transcatheter aotic valve implantation: the ATLANTIS 4D-CT substudy.
Available from: https://www.crtonline.org/presentation-detail/apixaban-vale-thrombosis-after-transcatheter-aorti [Last accessed on 8
Aug 2022].
44. Backer O, Dangas GD, Jilaihawi H, et al; GALILEO-4D investigators. Reduced leaflet motion after transcatheter aortic-valve
replacement. N Engl J Med 2020;382:130-9. DOI PubMed
45. Park H, Kang DY, Ahn JM, et al. Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual
antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement. BMJ
Open 2021;11:e042587. DOI PubMed PMC